07 Jul 2023 --- Bioscience company Chr. Hansen has adjusted its organic growth financial outlook upwards of 9-11%, following a healthy performance for the year’s first three quarters. Revenue amounted to €335 million (US$365 million), up 5% from €318 million (US$346 million) the previous financial year.
